- Home
- ALVR
ALVR
AlloVir Inc.
as 11-21-2024 12:30pm EST
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 87.7M | IPO Year: | 2020 |
| Target Price: | $1.00 | AVG Volume (30 days): | 563.5K |
| Analyst Decision: | Sell | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.87 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $2.48 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AlloVir Inc. (ALVR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sinha Vikas | ALVR | See Remarks | Nov 19 '24 | Sell | $0.55 | 3,186 | $1,747.52 | 1,140,894 | |
| Brainard Diana | ALVR | Chief Executive Officer | Nov 19 '24 | Sell | $0.55 | 8,706 | $4,775.24 | 723,363 | |
| Sinha Vikas | ALVR | See Remarks | Nov 5 '24 | Sell | $0.86 | 5,136 | $4,442.13 | 1,140,894 | |
| Brainard Diana | ALVR | Chief Executive Officer | Nov 5 '24 | Sell | $0.86 | 10,609 | $9,175.72 | 723,363 | |
| Miller Edward | ALVR | General Counsel | Oct 21 '24 | Sell | $0.77 | 1,401 | $1,082.80 | 214,969 | |
| Sinha Vikas | ALVR | See Remarks | Oct 21 '24 | Sell | $0.77 | 3,428 | $2,649.33 | 1,140,894 | |
| Hagen Brett R | ALVR | Chief Accounting Officer | Oct 21 '24 | Sell | $0.77 | 965 | $746.29 | 71,201 | |
| Brainard Diana | ALVR | Chief Executive Officer | Oct 21 '24 | Sell | $0.78 | 9,752 | $7,596.81 | 723,363 | |
| Miller Edward | ALVR | General Counsel | Oct 3 '24 | Sell | $0.81 | 377 | $307.18 | 214,969 | |
| Sinha Vikas | ALVR | See Remarks | Oct 3 '24 | Sell | $0.81 | 940 | $765.91 | 1,140,894 |
Latest AlloVir Inc. News
ALVR Breaking Stock News: Dive into ALVR Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
10 days ago
AlloVir and Kalaris enter merger to advance retinal disease therapies
MT Newswires
13 days ago
Sector Update: Health Care Stocks Edge Higher Premarket Friday
MT Newswires
13 days ago
Sector Update: Health Care
BioPharma Dive
13 days ago
Kalaris to go public via reverse merger with AlloVir
MT Newswires
13 days ago
AlloVir Signs Merger with Kalaris Therapeutics
GlobeNewswire
13 days ago
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
Simply Wall St.
22 days ago
Discovering Opportunities: AlloVir And 2 Other US Penny Stocks
GuruFocus.com
a month ago
Octagon Capital Advisors LP Increases Stake in AlloVir Inc
Compare ALVR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALVR AlloVir Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.